10 Must-Buy Non-Tech Stocks to Invest In

2. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Year to date Gain: 56.65%

Stock Upside Potential: 77.83%

Number of Hedge Fund Holders: 35

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a must-buy non-tech stock to invest in. On November 17, analysts at Wolfe Research initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) with a Peer Perform rating. According to the research firm, the stock is likely to trade in the $70 to $75 range until there is a resolution to the ongoing patent litigation and antitrust concerns.

Nevertheless, the research firm expects drug candidate relacorilant to drive upside following its PDUFA date for hypercortisolism on December 30, 2025. It expects the candidate drug for Cushing syndrome to impact the company’s long-term outlook positively. The remarks follow the company’s mixed third-quarter results on November 3.

Earnings per share came in at $0.16, beating consensus estimates of $0.13 but representing a significant drop from $0.41 per share delivered in the same quarter last year. On the other hand, revenues totaled $2097.6 million, compared with $182.5 million in the same quarter last year.

The third quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a record number of new prescriptions written for Korlym® and continued to add to our base of prescribers. […]Our financial results don’t fully reflect this surge in demand, given capacity constraints at our previous specialty pharmacy vendor. We have modified our 2025 revenue guidance to $800 – $850 million,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company that discovers, develops, and commercializes medications to treat serious metabolic, oncologic, and psychiatric disorders by modulating the effects of the stress hormone cortisol. Its lead product is Korlym (mifepristone), which is approved to treat hypercortisolism (Cushing’s syndrome).